The KIF13B Knouckout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population derived from the A-549 human lung adenocarcinoma cell line. This product features a heterogeneous pool of cells carrying diverse CRISPR/Cas9-mediated disruptions of the KIF13B gene, providing a robust loss-of-function model for studying gene function without the bias of clonal selection. The targeted gene encodes a plus-end directed kinesin-3 motor protein essential for microtubule-dependent transport of recycling endosomes, and its disruption enables detailed investigation of intracellular trafficking, cell migration, and related signaling pathways in a cancer-relevant context.
A-549 cells were originally established from the lung adenocarcinoma of a 58-year-old Caucasian male and serve as a widely used model for non-small cell lung cancer (NSCLC). These adherent cells retain characteristics of alveolar type II epithelium and are permissive for studying oncogenic processes such as proliferation, invasion, and drug response. Their well-characterized signaling networks and ease of genetic manipulation make A-549 cells an ideal host for CRISPR-based knockout studies, particularly for dissecting mechanisms of metastasis and endosomal trafficking within a pulmonary carcinoma background.
KIF13B encodes a molecular motor that is activated by the small GTPase Rab11a and functions downstream of PI3K/AKT signaling to regulate vesicular transport. It forms dynamic complexes with adaptor proteins including Rab11-FIP3, ??-actinin, and ??-catenin, which mediate the trafficking of critical cargoes such as ??1 integrin and MT1-MMP along microtubules. Through these interactions, KIF13B promotes actin cytoskeleton reorganization and cell migration, processes that are coordinately regulated by the endocytic recycling machinery comprising Rab25, EHD1, and EHBP1. Disruption of KIF13B therefore perturbs this entire network, offering a powerful tool to dissect these interconnected pathways.
In A-549 lung adenocarcinoma cells, disruption of KIF13B impairs the endosomal recycling of ??1 integrins, leading to reduced cell adhesion and migration. The loss of KIF13B also compromises MT1-MMP transport to the plasma membrane, diminishing matrix degradation and invasion, thereby attenuating the metastatic potential of these cells. This polyclonal knockout population thus provides a physiologically relevant model to examine how KIF13B-dependent vesicular transport governs the invasive behavior of NSCLC cells, yielding insights into the molecular underpinnings of cancer metastasis and identifying potential therapeutic targets.
This knockout cell population is suitable for a wide array of functional and mechanistic studies. Wound healing and transwell migration assays can quantitatively assess the impact of KIF13B loss on cell motility, while integrin internalization and recycling assays combined with immunofluorescence for endosomal markers such as Rab11a allow detailed tracking of cargo trafficking. Western blotting and RT-qPCR can monitor changes in downstream signaling mediators like phosphorylated AKT or ??-catenin, and live-cell imaging enables real-time analysis of vesicle transport dynamics. Moreover, the polyclonal nature makes these cells amenable to high-content screening for motor protein inhibitors, supporting drug target validation in cancer therapy. For further details or technical support, please contact Ascent Research.
